Advanced Therapeutics Pharmaceutical Outsourcing Market Report 2026

Advanced Therapeutics Pharmaceutical Outsourcing Market Overview

• Advanced Therapeutics Pharmaceutical Outsourcing market size has reached to $8.41 billion in 2025 • Expected to grow to $10.73 billion in 2030 at a compound annual growth rate (CAGR) of 5% • Growth Driver: Impact Of Cell and Gene Therapies On The Advanced Therapeutics Pharmaceutical Outsourcing Market • Market Trend: Strategic Partnerships In Advanced Therapeutics Pharmaceutical Outsourcing • North America was the largest region in 2025.

What Is Covered Under Advanced Therapeutics Pharmaceutical Outsourcing Market?

Advanced Therapeutic Pharmaceutical Outsourcing refers to contracting out specialized pharmaceutical services related to advanced therapeutic products. These products often include advanced therapies such as cell and gene therapies, personalized medicines, biologics, and other novel treatments. They are used to obtain specialized expertise and capabilities in producing, testing, and developing advanced therapeutic products. The main services of advanced therapeutics pharmaceutical outsourcing are contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs). Advanced therapeutics pharmaceutical outsourcing services provided to contract research organizations (CROs) can include a range of specialized offerings to support their work in the development and commercialization of advanced therapeutic products. These services are used for oncology, neurology, cardiology, infectious diseases, and other indications by outsourcing cell therapy, gene therapy, and RNA-based therapies for preclinical services, clinical services, commercial manufacturing and packaging applications.

What Is The Advanced Therapeutics Pharmaceutical Outsourcing Market Growth Forecast?

The advanced therapeutics pharmaceutical outsourcing market size is expected to see strong growth in the next few years. It will grow to $10.73 billion in 2030 at a compound annual growth rate (CAGR) of 5.0%. The growth in the forecast period can be attributed to growth in personalized medicine adoption, expansion of commercial-scale cell and gene therapies, increasing regulatory complexity, surge in biotech start-up funding, demand for faster time-to-market. Major trends in the forecast period include increasing outsourcing of cell and gene therapy manufacturing, rising demand for end-to-end cdmo services, expansion of specialized viral vector production capabilities, growing focus on regulatory and quality compliance support, accelerated clinical trial outsourcing for rare and complex indications.

What Is The Driver Of The Advanced Therapeutics Pharmaceutical Outsourcing Market?

The increasing adoption of cell and gene therapies is expected to propel the growth of the advanced therapeutics pharmaceutical outsourcing market going forward. Cell and gene therapies are innovative treatments that use living cells or genetic material to treat or cure diseases. Advanced therapeutics pharmaceutical outsourcing is used in cell and gene therapies to offer access to providers with proven track records and experienced personnel, saving companies time and resources in building their teams. For instance, in March 2024, according to the IQVIA Holdings Inc., a US-based provider of advanced analytics, technology solutions, and clinical research services for the life sciences and healthcare industries, global spending on cell and gene therapies surged to $5.9 billion in 2023, an increase of 38% from 2022. Therefore, the increasing adoption of cell and gene therapies is driving the growth of the advanced therapeutics pharmaceutical outsourcing industry.

Key Players In The Global Advanced Therapeutics Pharmaceutical Outsourcing Market

Major companies operating in the advanced therapeutics pharmaceutical outsourcing market are Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, IQVIA, ICON plc, SGS SA, Lonza Group, Parexel International Corporation, WuXi AppTec, Syneos Health, Catalent Inc., Charles River Laboratories International, Recipharm AB, Samsung Biologics, Vetter Pharma International GmbH, Medpace Holdings Inc., Fujifilm Diosynth Biotechnologies, AGC Biologics, Evotec SE, Piramal Pharma Solutions, Corden Pharma International LLC, Novotech Pty Ltd., Cytovance Biologics

Global Advanced Therapeutics Pharmaceutical Outsourcing Market Trends and Insights

Major companies operating in the advanced therapeutics pharmaceutical outsourcing market are focusing on strategic partnerships to provide reliable services to customers. A strategic partnership is a collaborative arrangement between two or more entities (typically businesses) formed to achieve mutually beneficial goals that each partner could not achieve independently. For instance, in January 2023, Lonza, a Switzerland-based manufacturing company for the pharmaceutical, biotechnology, and nutrition sectors, partnered with Context Therapeutics Inc., a US-based biopharmaceutical company advancing medicines for solid tumors. The partnership involves Lonza providing manufacturability assessment, gene, and cell line construction, and process development for the drug substance and drug product.

What Are Latest Mergers And Acquisitions In The Advanced Therapeutics Pharmaceutical Outsourcing Market?

In December 2023, Ajinomoto Co., Inc., a Japan-based provider of amino acids and biomanufacturing solutions, completed the acquisition of Forge Biologics Inc. for an undisclosed amount. Through this acquisition, Ajinomoto aims to strengthen its position in the gene therapy manufacturing market by expanding its viral vector production capabilities, enhancing its CDMO service portfolio, and accelerating innovation in advanced gene therapy development. Forge Biologics Inc. is a US-based gene therapy-focused CDMO specializing in adeno-associated virus manufacturing and end-to-end development services.

What Defines the Advanced Therapeutics Pharmaceutical Outsourcing Market?

The advanced therapeutics pharmaceutical outsourcing market includes revenues earned by entities by providing services such as research and development support, process development and manufacturing, comprehensive analytical testing and characterization, regulatory support, clinical manufacturing, commercial manufacturing, implementation of quality systems, consulting and strategic services. The market value includes the value of related goods sold by the service provider or included within the service offering.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Advanced Therapeutics Pharmaceutical Outsourcing Market Report 2026?

The advanced therapeutics pharmaceutical outsourcing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the advanced therapeutics pharmaceutical outsourcing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.